The global systemic lupus erythematosus (SLE) drugs market size reached US$ 2.7 billion in 2023. The market is projected to reach US$ 4.5 billion by 2032, exhibiting a growth rate (CAGR) of 6.01% during 2023-2032.The increasing number of patients suffering from SLE, rising public awareness campaigns, and the easy availability of generic drugs represent some of the key factors driving the market.
Systemic lupus erythematosus (SLE) is an autoimmune medical condition characterized by protean clinical manifestations, multisystem inflammation (MIS), and a relapsing and remitting course (RRMS). It affects numerous parts of the body, including the skin, joints, kidneys, and brain. It is generally caused due to various genetic, environmental, and hormonal factors. Its symptoms include fatigue, joint pain and swelling, headache, rashes, hair loss, anemia, blood clotting, and fever. SLE is diagnosed by a healthcare provider using symptom assessments, physical examinations, chest X-rays, urinalysis, and blood tests. Its symptoms can be eased using anti-inflammatory drugs for joint pain and stiffness, steroid creams for rashes, corticosteroids to minimize the immune response, and antimalarial drugs for skin problems. It also uses disease-modifying drugs and targeted immune system agents for more severe cases. Besides this, it is treated using various immunosuppressive drugs that inhibit the activity of the immune system.
2. What is the expected growth rate of the global Systemic Lupus Erythematosus (SLE) drugs market during 2024-2032?
3. What are the key factors driving the global Systemic Lupus Erythematosus (SLE) drugs market?
4. What has been the impact of COVID-19 on the global Systemic Lupus Erythematosus (SLE) drugs market?
5. What is the breakup of the global Systemic Lupus Erythematosus (SLE) drugs market based on the drug class?
6. What is the breakup of the global Systemic Lupus Erythematosus (SLE) drugs market based on the mode of delivery?
7. What are the key regions in the global Systemic Lupus Erythematosus (SLE) drugs market?
8. Who are the key players/companies in the global Systemic Lupus Erythematosus (SLE) drugs market?
Systemic lupus erythematosus (SLE) is an autoimmune medical condition characterized by protean clinical manifestations, multisystem inflammation (MIS), and a relapsing and remitting course (RRMS). It affects numerous parts of the body, including the skin, joints, kidneys, and brain. It is generally caused due to various genetic, environmental, and hormonal factors. Its symptoms include fatigue, joint pain and swelling, headache, rashes, hair loss, anemia, blood clotting, and fever. SLE is diagnosed by a healthcare provider using symptom assessments, physical examinations, chest X-rays, urinalysis, and blood tests. Its symptoms can be eased using anti-inflammatory drugs for joint pain and stiffness, steroid creams for rashes, corticosteroids to minimize the immune response, and antimalarial drugs for skin problems. It also uses disease-modifying drugs and targeted immune system agents for more severe cases. Besides this, it is treated using various immunosuppressive drugs that inhibit the activity of the immune system.
Systemic Lupus Erythematosus (SLE) Drugs Market Trends
The increasing prevalence of autoimmune diseases among individuals and the rising number of patients suffering from SLE represents one of the major factors driving the demand for SLE drugs around the world. Moreover, the rising number of research and diagnostics institutes are undertaking measures and introducing public awareness campaigns to educate individuals about SLE and its possible treatments. In addition, governments and non-governmental organizations (NGOs) of numerous countries are investing in various programs to develop novel therapeutics and identify relevant drug targets for the treatment of SLE. This, coupled with the increasing financing to improve healthcare infrastructure and diagnostic technologies worldwide, is impelling the market growth. Apart from this, the easy availability of various generic drugs for relieving pain, inflammation, and stiffness associated with SLE through offline and online retail channels is favoring the market growth. They generally involve over the counter (OTC) and prescription-based nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen (Motrin), naproxen, celecoxib (Celebrex), diclofenac (Voltaren), diflunisal (Dolobid), and piroxicam (Feldene). Furthermore, the increasing use of Hydroxychloroquine drugs is contributing to the market growth. Besides this, the growing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of SLE is influencing the overall sales of SLE drugs.Key Market Segmentation:
The report provides an analysis of the key trends in each segment of the global systemic lupus erythematosus (SLE) drugs market, along with forecasts at the global, regional, and country level from 2023-2032. The report has categorized the market based on drug class and mode of delivery.Drug Class Insights:
- Antimalarials Drugs
- Chloroquine
- Hydroxychloroquine
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Cytotoxic and Immunosuppressive Drugs
- Cyclophosphamide
- Methotrexate
- Mycophenolate Mofetil
- Tacrolimus
- Cyclosporine
- Biologics
- Others
Mode of Delivery Insights:
- Intravenous
- Subcutaneous
- Oral
Regional Insights:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global systemic lupus erythematosus (SLE) drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AstraZeneca Plc, Aurinia Pharmaceuticals Inc., GSK plc, and ImmuPharma Plc.Key Questions Answered in This Report
1. How big is the global Systemic Lupus Erythematosus (SLE) drugs market?2. What is the expected growth rate of the global Systemic Lupus Erythematosus (SLE) drugs market during 2024-2032?
3. What are the key factors driving the global Systemic Lupus Erythematosus (SLE) drugs market?
4. What has been the impact of COVID-19 on the global Systemic Lupus Erythematosus (SLE) drugs market?
5. What is the breakup of the global Systemic Lupus Erythematosus (SLE) drugs market based on the drug class?
6. What is the breakup of the global Systemic Lupus Erythematosus (SLE) drugs market based on the mode of delivery?
7. What are the key regions in the global Systemic Lupus Erythematosus (SLE) drugs market?
8. Who are the key players/companies in the global Systemic Lupus Erythematosus (SLE) drugs market?
Table of Contents
1 Preface3 Executive Summary10 Value Chain Analysis12 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Systemic Lupus Erythematosus (SLE) Drugs Market
6 Market Breakup by Drug Class
7 Market Breakup by Mode of Delivery
8 Market Breakup by Region
9 Drivers, Restraints, and Opportunities
11 Porters Five Forces Analysis
13 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- AstraZeneca Plc
- Aurinia Pharmaceuticals Inc.
- GSK plc
- ImmuPharma Plc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 142 |
| Published | January 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 2.7 Billion |
| Forecasted Market Value ( USD | $ 4.5 Billion |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 4 |
